December 2007 - The Indian Society for Parasitology

Chemotherapy of human trichomoniasis91Schmid G, Narcisi E, Mosure D, Secor WE, Higgins J and purpuromycin as potential topical agents for vaginalMoreno H. 2001. Prevalence of metronidazole-resistant infections. J Med Chem 40:967-971.Trichomonas vaginalis in a gynecology clinic. J Reprod MedTurner AC and Lushbaugh WB. 1988. Trichomonas vaginalis:Schumacher MA, Lau AO and Johnson PJ. 2003. Structural basis characterization of its glutamate dehydrogenase. Expof core promoter recognition in a primitive eukaryote. Cell. Parasitol 67:47-53.115:370-372.Upcroft P and Upcroft JA. 2001. Drug targets and mechanisms ofSchwebke JR. 2002. Update of trichomoniasis. Sex Transm resistance in the anaerobic protozoa. Clin Microbiol RevInfect 78:378-379. 14:150-164.Schwebke JR and Burgess D. 2004. Trichomoniasis. Clin U.S. Food and Drug Administration. 2004. Index to drug-Microbiol Rev 17:794-803.specific information. http://www.fda.gov/cder/Sobel JD, Nyirjesy P and Brown W. 2001. Tinidazole therapy forconsumerinfo/tindamax.htm.metronidazole-resistant vaginal trichomoniasis. Clin Infect Vidakovic M, Crossnoe CR, Neidre C, Kim K, Krause KL andDis 33:1341-1346.Germanas JP. 2003. Reactivity of reduced [2Fe-2S]ferredoxins parallels host susceptibility to nitroimidazoles.Solano-Gonzaleza E, Alvarez-Sanchezb ME, Avila-GonzalezcAntimicrob Agents Chemother 47:302-308.L, Rodriguez-Vargasa VH, Arroyoc R and Ortega-Lopez J.2006. Location of the cell-binding domain of CP65, a 65 kDa Westrop GD, Goodall G, Mottram JC and Coombs GH. 2006.cysteine proteinase involved in Trichomonas vaginalis Cysteine biosynthesis in Trichomonas vaginalis involvescytotoxicity. Int J Biochem Cell Biol 38:2114-2127.cysteine synthase utilizing o-phosphoserine. J Biol ChemStrosselli S, Spadari S, Walker RT, Basnak I and Focher F. 1998.281:25062-25075.Trichomonas vaginalis thymidine kinase: purification, World Health Organization. 2001. Global prevalence andcharacterization and search for inhibitors. Biochem J 334:15- incidence of selected curable sexually transmitted infections.22. G e n e v a , S w i t z e r l a n d . h t t p : / / w w w. w h o . i n t /Sutak R, Dolezal P, Fiumera HL, Hrdy I, Dancis A, Delgadillodocstore/hiv/GRSTI/006.htm.Correa M, Johnson PJ, Müller M and Tachezy J. 2004. Yadav M, Dubey ML, Gupta I, Bhatti G and Malla N. 2007.Mitochondrial-type assembly of FeS centers in the Cysteine proteinase 30 in clinical isolates of T. vaginalis fromhydrogenosomes of the amitochondriate eukaryote symptomatic and asymptomatic infected women. ExpTrichomonas vaginalis. 101:10368-10373. Parasitol 116:399-406.Sutcliffe S, Giovannucci E, Alderete JF, Chang TH, Gaydos CA, Yarlett N and Bacchi CJ. 1988. Effect of DL-alpha-Zenilman JM, Marzo AM, Willett WC and Platz EA. 2006. difluoromethylornithine on polyamine synthesis andPlasma antibodies against Trichomonas vaginalis and interconversion in Trichomonas vaginalis grown in a semisubsequentrisk of prostate cancer. Cancer Epidemiol defined medium. Mol Biochem Parasitol 31:1-9.Biomarker Preven 15:939-945.Zang Y, Wen-Hu W, Shaw-Wen W, Ealick SE and Wang CC.Tachezy J, Kulda J and Tomokova E. 1993. Aerobic resistance of 2005. Identification of a subversive substrate of TrichomonasTrichomonas vaginalis to metronidazole induced in vitro. vaginalis purine nucleoside phosphorylase and the crystalParasitol 106:31-37.structure of the enzyme-substrate complex. J Biol ChemThappa DM. 2006. Evolution of venereology in India. Ind J280:22318-22325.Dermatol Venerol Leprol 72:187-196.Zariffard MR, Harwani S, Novak RM, Graham PJ, Ji X and SpearGT. 2004. Trichomonas vaginalis infection activates cellsTrani A, Dallanoce C, Panzone G, Ripamonti F, Goldstein BPthrough toll-like receptor 4. Clin Immunol 111:103-107.and Ciabatti R. 1997. Semisynthetic derivatives of